ACTivating the Immune Response in Ovarian CaNcer

Launched by GYNAECOLOGISCH ONCOLOGISCH CENTRUM ZUID · Sep 23, 2024

Keywords

ClinConnect Summary

This clinical trial, called "ACTivating the Immune Response in Ovarian CaNcer," aims to better understand how the immune system works in women with ovarian cancer compared to those without cancer. Researchers want to see how certain immune cells behave in patients who are undergoing different types of surgery for ovarian cancer. They believe that the immune response in these patients might be weakened, which could affect how the cancer progresses. By studying blood, bone marrow, and other samples, they hope to learn more about the immune system's role in ovarian cancer.

To participate in this study, women must be at least 18 years old and newly diagnosed with ovarian cancer, planning to have surgery. They will also include women having surgery for non-cancerous conditions as a comparison group. Participants can expect to provide blood samples, undergo a bone marrow aspiration, and possibly have tumor or spleen biopsies if they are cancer patients. It's important to note that certain individuals, such as those with severe health issues, pregnant women, or those taking specific medications that affect the immune system, will not be eligible for this study. The trial is not yet recruiting participants, but it aims to shed light on how to better activate the immune system in ovarian cancer patients.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Subjects should be at least 18 years old and mentally competent;
• • Newly diagnosed patients with OC who go for primary debulking surgery or patients with OC who are scheduled for interval debulking;
• • Controls: women who undergo surgery for benign gynaecological conditions under general anaesthesia.
• Exclusion Criteria:
• • Mentally incompetent;
• • Pregnant or breastfeeding;
• • Known inflammatory of infectious diseases or an immunosuppressive status;
• • Using medication interfering with the immune system;
• • Severe comorbidities: other active malignancy (except for basal cell carcinoma and other in situ carcinomas);
• • Serious psychiatric pathology;
• • A self reported alcohol consumption of \>21 units per week.